Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.33 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2176453 | 1.00 | RAB9A (0.34) | RAB9ALMNAMAPK10MEN1KMT2A | |
| SCHEMBL29386113 | 0.83 | MAPT (0.36) | RAB9ALMNAMEN1KMT2AEHMT2 | |
| SCHEMBL42875 | 0.83 | MAPT (0.36) | RAB9ALMNAMEN1KMT2AEHMT2 | |
| SCHEMBL5153054 | 0.80 | SMN1; SMN2 (0.39) | RAB9ALMNAMEN1KMT2AEHMT2 | |
| SCHEMBL8341133 | 0.77 | KDM4E (0.39) | MEN1KMT2ASMN1; SMN2KDM4ETSHR | |
| SCHEMBL29351145 | 0.77 | LMNA (0.38) | RAB9ALMNAMEN1KMT2AEHMT2 | |
| SCHEMBL321113 | 0.77 | LMNA (0.38) | RAB9ALMNAMEN1KMT2AEHMT2 | |
| SCHEMBL8610607 | 0.77 | LMNA (0.38) | RAB9ALMNAMEN1KMT2AEHMT2 | |
| SCHEMBL1746858 | 0.76 | ALDH1A1 (0.35) | RAB9ALMNAMAPK10MEN1KMT2A | |
| SCHEMBL5502675 | 0.76 | LMNA (0.36) | RAB9ALMNAMAPK10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 362 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120150966-A | Method and device for collaborative management of uplink and downlink of vehicle-road collaborative data chain | 上海交通大学 | 2025-06-13 | — | — | CN | claimed |
| EP-4746899-A1 | TREATMENT OF CANCER PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH TROP-2 TARGETING ADC | Iovance Biotherapeutics, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4743565-A2 | CYTOKINE ENCODING LENTIVIRAL VECTORS AND USES THEREOF FOR MAKING TUMOR INFILTRATING LYMPHOCYTES | Iovance Biotherapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| CN-122036912-A | Cytokine conjugates for the treatment of proliferative and infectious diseases | 辛索克斯公司 | 2026-05-15 | — | — | CN | disclosed |
| WO-2026102297-A1 | ANTIBODY OLIGONUCLEOTIDE CONJUGATES FOR TREATING DISEASE | Fulcrum Therapeutics, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4735602-A2 | COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES ABSTRACT | Atrium Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735051-A1 | COMPOSITIONS AND METHODS OF USING PLN-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | Atrium Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4720081-A1 | CONJUGATE COMPOSITIONS COMPRISING PHOSPHORYL GUANIDINE LINKAGES AND USES THEREOF | Avidity Biosciences, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12583932-B2 | CD38 and ICAM1 antibodies and uses thereof | VIRTUOSO BINCO, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4705346-A2 | ANTI-CCR8 ANTIBODIES, CONJUGATES, AND USES THEREOF | Abilita Bio, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-11293868-B2 | Ratiometric fluorescence imaging methods | AVELAS BIOSCIENCES, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| US-20220096647-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2022-03-31 | — | — | US | disclosed |
| US-20220088213-A1 | DRUG DELIVERY SYSTEM USING PH-DEPENDENT CELL-PENETRATING PEPTIDES, AND COMPOSITE THEREOF WITH DRUG | KIM SUNG CHUN (KR) | 2022-03-24 | — | — | US | disclosed |
| US-20220089768-A1 | MULTI-SPECIFIC PROTEIN MOLECULES AND USES THEREOF | TRIO PHARMACEUTICALS, INC. | 2022-03-24 | — | — | US | disclosed |
| US-20220072145-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | AVIDITY BIOSCIENCES, INC. | 2022-03-10 | — | — | US | disclosed |
| EP-3963091-A1 | METHODS AND SYSTEMS FOR INTEGRATED ON-CHIP SINGLE-MOLECULE DETECTION | Nautilus Biotechnology, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| US-20220062434-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2022-03-03 | — | — | US | disclosed |
| EP-3959319-A1 | NUCLEIC ACID COMPOSITIONS AND METHODS OF MULTI-EXON SKIPPING | Avidity Biosciences, Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| US-20220059202-A1 | SYSTEMS AND METHODS FOR COORDINATING MANUFACTURING OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY | IOVANCE BIOTHERAPEUTICS, INC. | 2022-02-24 | — | — | US | disclosed |
| CN-114072171-A | Multivalent immunotherapeutic compositions and methods for treating WT 1-positive cancers | SLSG有限责任公司 | 2022-02-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220088213-A1 | DRUG DELIVERY SYSTEM USING PH-DEPENDENT CELL-PENETRATING PEPTIDES, AND COMPOSITE THEREOF WITH DRUG | SLC7A1, ABCB11, HDGF | RAB9A 1277/4885LMNA 3119/4885MAPK10 1665/4885 |
| US-11293868-B2 | Ratiometric fluorescence imaging methods | FLI1, HNRNPF, HNRNPR | RAB9A 613/4885LMNA 1241/4885MAPK10 4443/4885 |
| US-20220072145-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | NSUN2, UPF1, SNRPE | RAB9A 3548/4885LMNA 126/4885MAPK10 4171/4885 |
| US-20220096647-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY | MTPN, MYOF, TNNC1 | RAB9A 3444/4885LMNA 52/4885MAPK10 2668/4885 |
| US-12583932-B2 | CD38 and ICAM1 antibodies and uses thereof | FCGR2A, FCGR3B, FCGR1A | RAB9A 3881/4885LMNA 1047/4885MAPK10 4340/4885 |
| US-20220062434-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY | MTPN, MYOF, TNNC1 | RAB9A 3444/4885LMNA 52/4885MAPK10 2668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.